Abstract
Purpose :
To compare the safety and efficacy of the Preserflo microshunt in patients with primary high pressure (HPG) and normal pressure (NPG) glaucoma after the first year of follow up.
Methods :
Institutional prospective interventional cohort study comparing consecutively included eyes with HPG and NPG, which had received the PRESERFLO MicroShunt for further lowering intraocular pressure (IOP). Outcome measures: mean diurnal IOP (mdIOP, mean of 6 measurements), peak IOP, and IOP fluctuations and adverse events one year after surgery. Statistical analyses using SPSS 25, Mann-Whitney U test and Wilcoxon test.
Results :
Twenty-one patients in the HPG and 9 in the NPG were analyzed and compared. Median [Q25, Q75] mdIOP (mmHg) dropped from 18.7 [15.5-27.3] to 11.2 [9.0-14.4] in the HPG and from 13.8 [12.7-16.3] to 9.7 [7.8-11.2] in the NPG group 1 year after surgery. Reduction of mdIOP (P=.08), peak IOP (P=.09), and fluctuations (P=.1) were not statistically significantly different between both groups. None of the patients experienced severe adverse events.
Conclusions :
The PRESERFLO MicroShunt is effective even in patients with rather low baseline IOP.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.